COMIRNATY® (BNT162b2)
COVID-19 Prevention
Key Facts
About Fosun Pharma
Fosun Pharma's mission is to be the global leading integrator of pharmaceutical and healthcare innovation, delivering 'Better Health for Families Worldwide.' The company has achieved significant milestones, including China's first approved CAR-T cell therapy (Yi Kai Da), a leading biosimilar portfolio, and the WHO-recommended antimalarial Artesun®. Its strategy combines independent R&D with aggressive in-licensing and global partnerships to build a diversified portfolio across therapeutics, vaccines, and diagnostics, supported by a vast commercial network through its stake in Sinopharm.
View full company profileTherapeutic Areas
Other COVID-19 Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Intranasal COVID Vaccine | Virpax Pharmaceuticals | Research |
| COVID-19 Vaccine Trials | DM Clinical Research | Not Specified |
| SARS-CoV-2 Vaccine | Epygen Biotech | Not Disclosed |
| COVAXIN | Bharat Biotech | Commercial |
| iNCOVACC | Bharat Biotech | Commercial |
| IRT Platform (e.g., COVID-19) | Biological Mimetics | Research/Pre-clinical |
| Replicon RNA COVID-19 Vaccine | BIKEN Group | Preclinical/Development |
| Convidecia Air® (XBB.1.5 Variant) | CanSino Biologics | Approved |
| COVID-19 Vaccine | Recbio Technology | Not specified |
| BBIBP-CorV | Sinopharm | Approved |
| Recombinant Protein COVID-19 Vaccine | Sinopharm | Approved |
| COVID-19 mRNA Vaccine (SYS6006) | CSPC Innovation Pharmaceutical | Marketed |